Table of Contents
Lord’s Mark Industries Unlisted Share
BUY
₹ 62.50
SELL
₹ 69.00
Lords Mark Industries shares may be in a downtrend due to several factors, including potential supply exceeding demand in the market, the unlisted nature of the shares, and concerns about the company's financial performance. These factors can lead to lower liquidity, price volatility, and regulatory risks for investors.
As on May 30, 2026, we are buying shares of the LORD'S MARK INDUSTRIES LIMITED for ₹ 62.50 and selling them for ₹ 69.00 per share.
About Lord’s Mark Industries Unlisted Share
Lords Mark Group, established in 1998 as a paper business, has evolved into a diversified conglomerate. Today, the group focuses on high-growth sectors—primarily In-Vitro Diagnostics (IVD), MedTech, and Renewable Energy.
With a strategic shift away from legacy businesses, Lords is actively divesting its paper division and planning a reverse merger to enter the listed space, signaling aggressive expansion and transformation.
Business Divisions
a) IVD / MedTech Division
-
Focused on rapid diagnostics and non-communicable disease management
-
Portfolio includes 34+ rapid test kits, surgical consumables, and biochemicals
-
Expanding into genome testing and B2C with E-smart clinics
b) Renewable Energy / LED Division
-
Market leader in rooftop solar installations in UP and Bihar
-
Strategic partnerships with Philips and defense projects
-
500 MW solar project target over 7 years; current order book: ₹2,000+ Cr
c) Paper Division (To Be Divested)
-
Currently contributes 18% of revenue
-
Planned divestment to focus on high-growth MedTech and solar verticals
Financial Highlights (FY22–FY24)
1. Revenue Growth:
Revenue surged from ₹213 Cr (FY22) to ₹555 Cr (FY24), indicating a CAGR of 28%.
2. Profitability Metrics:
EBITDA improved from ₹13.1 Cr to ₹38 Cr with a CAGR of 62%, while PAT rose from ₹4.2 Cr to ₹11.3 Cr (CAGR 93%).
3. Margin Expansion:
Gross margins increased from 8.92% to 13.33%, and OPM remained stable above 6%, reflecting operational efficiencies.
4. EPS Movement:
EPS stood at ₹1.01 in FY24, rising from ₹0.82 in FY23, despite equity dilution.
5. Strong Asset Base:
Total assets grew from ₹220 Cr to ₹357 Cr, with fixed assets rising from ₹18.8 Cr to ₹47 Cr.
6. Borrowings & Leverage:
Borrowings increased from ₹123 Cr (FY22) to ₹216 Cr (FY24), funding aggressive expansion.
7. Capital Structure:
Share capital expanded from ₹5 Cr to ₹56.2 Cr, while reserves reached ₹32.6 Cr, indicating equity infusions to support growth.
Pros
- High CAGR in PAT and EBITDA, reflecting strong profitability momentum
- Robust Order Book (₹2,000+ Cr) across solar and healthcare segments
- Strategic Industry Shift towards IVD/MedTech and Renewable Energy sectors
Cons
- Rising Finance Costs from ₹6 Cr to ₹18.2 Cr, impacting net margins
- High Debt Levels due to expansion-led borrowings
- Equity Dilution from ₹5 Cr to ₹56.2 Cr may affect existing shareholder value
Key Details
| Field | Value |
|---|---|
| Company Name | |
| CIN | |
| ISIN | |
| Status | |
| Company Type | |
| Category | |
| Paid Up Capital | - |
Financials
Promoters or Management
Annual Reports
DRHP
Frequently Asked Questions
Unlisted Market Blogs
Read the latest blogs and trends in the market regarding Unlisted shares